Novartis Deepens Its Commitment To Biologics With MorphoSys Deal Worth Up To $1 Billion
This article was originally published in The Pink Sheet Daily
Executive Summary
German mAb company’s single-partner plan includes letting deals expire with other pharmas such as Bayer Schering and J&J, as well as upping internal pipeline investments.